PL3794042T3 - Koniugat przeciwciało-lek przeciwciało skierowane przeciwko muc1 - eksatekan - Google Patents
Koniugat przeciwciało-lek przeciwciało skierowane przeciwko muc1 - eksatekanInfo
- Publication number
- PL3794042T3 PL3794042T3 PL19724824.8T PL19724824T PL3794042T3 PL 3794042 T3 PL3794042 T3 PL 3794042T3 PL 19724824 T PL19724824 T PL 19724824T PL 3794042 T3 PL3794042 T3 PL 3794042T3
- Authority
- PL
- Poland
- Prior art keywords
- exatecan
- muc1
- antibody
- drug conjugate
- conjugate
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
- 229950009429 exatecan Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18173253 | 2018-05-18 | ||
PCT/EP2019/062758 WO2019219891A1 (en) | 2018-05-18 | 2019-05-17 | Anti-muc1 antibody-drug conjugate |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3794042T3 true PL3794042T3 (pl) | 2024-06-10 |
Family
ID=62217845
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL19724502.0T PL3794041T3 (pl) | 2018-05-18 | 2019-05-17 | Przeciwciało anty-muc1 |
PL19724824.8T PL3794042T3 (pl) | 2018-05-18 | 2019-05-17 | Koniugat przeciwciało-lek przeciwciało skierowane przeciwko muc1 - eksatekan |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL19724502.0T PL3794041T3 (pl) | 2018-05-18 | 2019-05-17 | Przeciwciało anty-muc1 |
Country Status (25)
Country | Link |
---|---|
US (4) | US20210221910A1 (pl) |
EP (4) | EP3794041B1 (pl) |
JP (3) | JP7519910B2 (pl) |
KR (2) | KR20210010565A (pl) |
CN (3) | CN117815404A (pl) |
AU (2) | AU2019270457A1 (pl) |
BR (2) | BR112020023373A2 (pl) |
CA (2) | CA3100745A1 (pl) |
CO (2) | CO2020013664A2 (pl) |
DK (1) | DK3794042T5 (pl) |
ES (1) | ES2951674T3 (pl) |
FI (1) | FI3794042T3 (pl) |
HR (1) | HRP20230787T1 (pl) |
HU (1) | HUE063066T2 (pl) |
LT (1) | LT3794042T (pl) |
MX (2) | MX2020011996A (pl) |
PH (2) | PH12020551969A1 (pl) |
PL (2) | PL3794041T3 (pl) |
PT (1) | PT3794042T (pl) |
RS (2) | RS64379B1 (pl) |
SG (2) | SG11202010496WA (pl) |
SI (1) | SI3794042T1 (pl) |
TW (3) | TWI825098B (pl) |
WO (2) | WO2019219889A1 (pl) |
ZA (1) | ZA202006684B (pl) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202010496WA (en) | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
BR112021001509A2 (pt) * | 2018-07-31 | 2021-04-27 | Daiichi Sankyo Company, Limited | agente terapêutico para um tumor de cérebro metastásico |
TW202116356A (zh) | 2019-07-10 | 2021-05-01 | 美商斯布雷克薩三號公司 | 作為治療劑之微管靶向藥劑之肽結合物 |
MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
CA3183184A1 (en) * | 2020-07-13 | 2022-01-20 | Regeneron Pharmaceuticals, Inc. | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
CN113941007B (zh) * | 2020-07-16 | 2024-06-07 | 成都科岭源医药技术有限公司 | 一种串联的双药物链接组装单元及其应用 |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
CN116059339B (zh) * | 2021-11-04 | 2023-09-22 | 元本(珠海横琴)生物科技有限公司 | 一种治疗和预防癌症的药物和应用 |
AU2023207960A1 (en) * | 2022-01-12 | 2024-07-11 | Regeneron Pharmaceuticals, Inc. | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
WO2023201234A2 (en) * | 2022-04-12 | 2023-10-19 | Minerva Biotechnologies Corporation | Anti-variable muc1* antibodies and uses thereof |
WO2023209591A1 (en) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
Family Cites Families (192)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US4931275A (en) | 1985-12-02 | 1990-06-05 | Yeda Research & Development Co., Ltd. | Anti-tumor vaccines and their preparation |
US5683674A (en) | 1987-01-07 | 1997-11-04 | Imperial Cancer Research Technology Ltd. | Antibody against human mucin core protein and method of preparing and using same |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5637770A (en) | 1991-01-16 | 1997-06-10 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic compound |
JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
ES2194838T3 (es) | 1991-02-27 | 2003-12-01 | Micromet Ag | Enlazadores peptidicos ricos en serina. |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
GB9200415D0 (en) | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Inactivation of cytotoxic drugs |
JP3698370B2 (ja) | 1992-04-13 | 2005-09-21 | ダナ−ファーバー キャンサー インスティチュート インク | 癌腫抗原用抗体 |
JP3359955B2 (ja) | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
US5804187A (en) | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
ATE301201T1 (de) | 1993-06-07 | 2005-08-15 | Vical Inc | Für die gentherapie verwendbare plasmide |
DE4329004A1 (de) | 1993-08-28 | 1995-03-09 | Max Delbrueck Centrum | Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis |
AU7965694A (en) | 1993-10-15 | 1995-05-04 | Curators Of The University Of Missouri, The | Dna encoding the human p2u receptor and null cells expressing p2u receptors |
US5443953A (en) | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
JPH08337584A (ja) | 1995-04-10 | 1996-12-24 | Dai Ichi Seiyaku Co Ltd | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
WO1997000957A1 (en) | 1995-06-23 | 1997-01-09 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
JPH1095802A (ja) | 1995-12-28 | 1998-04-14 | Tanabe Seiyaku Co Ltd | カンプトテシン誘導体 |
CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
EP0906444A1 (de) | 1996-04-19 | 1999-04-07 | Gabriele Pecher | Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine |
TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
JPH1171280A (ja) | 1997-06-26 | 1999-03-16 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
US6172213B1 (en) | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
JPH1192405A (ja) | 1997-09-19 | 1999-04-06 | Dai Ichi Seiyaku Co Ltd | 薬物複合体 |
EP1987845B1 (en) | 1997-11-20 | 2012-03-21 | Vical Incorporated | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor. |
US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
EP1080732A4 (en) | 1998-05-22 | 2004-08-25 | Daiichi Seiyaku Co | DRUG COMPOSITION |
CA2348931A1 (en) | 1998-10-30 | 2000-05-11 | Daiichi Pharmaceutical Co., Ltd. | Dds compound and method for measurement thereof |
US6465220B1 (en) | 1998-12-21 | 2002-10-15 | Glycozym Aps | Glycosylation using GalNac-T4 transferase |
AUPP816899A0 (en) | 1999-01-14 | 1999-02-11 | Food Technology Innovations Pty Limited | Improved microbial products |
EP1399538A2 (en) | 1999-03-02 | 2004-03-24 | Human Genome Sciences, Inc. | Engineering intracellular sialylation pathways |
DK1167537T3 (da) | 1999-03-30 | 2008-11-10 | Japan Tobacco Inc | Fremgangsmåde til fremstilling af et monoklonalt antistof |
ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
EP2283866B1 (en) | 1999-06-25 | 2015-02-25 | Genentech, Inc. | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
DE60018761T2 (de) | 1999-08-18 | 2006-02-02 | Altarex Medical Corp., Edmonton | Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung |
EP1216055A2 (en) | 1999-09-30 | 2002-06-26 | Corixa Corporation | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
JP2002060351A (ja) | 2000-03-22 | 2002-02-26 | Dai Ichi Seiyaku Co Ltd | 水酸基を有する薬物を含むdds化合物 |
US20020146750A1 (en) | 2000-03-30 | 2002-10-10 | Hoogenboom Hendricus R.J.M. | Mucin-1 specific binding members and methods of use thereof |
GB2362531A (en) | 2000-05-15 | 2001-11-21 | Nokia Mobile Phones Ltd | Indicating the temporal order of reference frames in a video sequence |
FR2809312B1 (fr) | 2000-05-25 | 2002-07-12 | Gervais Danone Sa | Utilisation de l. casei dans des compositions immunostimulantes |
MXPA02012791A (es) | 2000-06-29 | 2003-12-11 | Daiichi Seiyaku Co | Compuestos dds y metodo para prepararlo. |
CN1556712A (zh) | 2000-07-13 | 2004-12-22 | ��һ��������ҩ��ʽ���� | 含dds化合物的药用组合物 |
FR2814096B1 (fr) | 2000-09-15 | 2002-12-27 | Montupet Sa | Procede de fabrication de pieces de fonderie munies d'inserts avec cohesion mecanique piece/insert amelioree, et insert utilisable dans un tel procede |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
GB0029360D0 (en) | 2000-12-01 | 2001-01-17 | Univ Nottingham | Humanised antibodies and uses thereof |
JPWO2002061118A1 (ja) | 2001-02-01 | 2004-06-03 | 株式会社ヤクルト本社 | 発酵乳飲食品中のビフィドバクテリウム属細菌の腸内到達度評価方法 |
US7183388B2 (en) | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
DE10139428A1 (de) | 2001-08-17 | 2003-03-27 | Nemod Immuntherapie Ag | Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika |
CA2451998A1 (en) * | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
AU2002336981A1 (en) | 2001-08-17 | 2003-03-03 | Charite | Glycoconjugates of sialic acid derivates, methods for their production and use thereof |
TWI313609B (en) | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
DK1438336T3 (da) | 2001-10-22 | 2006-10-02 | Applied Research Systems | Gonadotropiner til follikeldannelse |
GB0125473D0 (en) | 2001-10-24 | 2001-12-12 | Syngenta Ltd | Chemical process |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
WO2003044051A1 (en) | 2001-11-20 | 2003-05-30 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
JP2005511627A (ja) | 2001-11-20 | 2005-04-28 | シアトル ジェネティクス,インコーポレーテッド | 抗cd30抗体を使用する免疫学的疾患の治療 |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
DK3483183T3 (da) | 2002-03-01 | 2021-06-21 | Immunomedics Inc | Immunokonjugat omfattende humaniserede rs7-antistoffer |
US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
GB0212046D0 (en) | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
DK1529060T3 (en) | 2002-07-22 | 2014-12-15 | Glycotope Gmbh | PROCEDURE FOR PREPARING AN IMMUNSTIMULATORY MUCIN (MUC1) |
WO2004018659A1 (en) | 2002-08-16 | 2004-03-04 | Glycotope Gmbh | Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds |
DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
WO2004054622A1 (en) | 2002-12-13 | 2004-07-01 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US7785594B2 (en) | 2003-08-14 | 2010-08-31 | Life Sciences Research Partners Vzw | Factor VIII inhibitory antibodies with reduced glycosylation |
WO2005017130A2 (en) | 2003-08-18 | 2005-02-24 | Glycotope Gmbh | Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof |
FR2861080B1 (fr) | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
US20050203010A1 (en) | 2003-11-14 | 2005-09-15 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
WO2005080585A1 (en) | 2004-02-13 | 2005-09-01 | Glycotope Gmbh | Highly active glycoproteins-process conditions and an efficient method for their production |
EP2033645A1 (en) | 2004-02-26 | 2009-03-11 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
US7837980B2 (en) | 2004-03-02 | 2010-11-23 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
SI2301576T1 (sl) * | 2004-03-29 | 2013-02-28 | Abbott Biotherapeutics Corp. | Terapevtska uporaba protiteles proti CS1 |
US20060051353A1 (en) | 2004-05-14 | 2006-03-09 | Jean-Frederic Colombel | Methods and compositions to evaluate antibody treatment response |
BRPI0510909A2 (pt) | 2004-05-19 | 2008-12-16 | Medarex Inc | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor |
CA2567520A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Maytansinoid-antibody conjugates |
PT1771482E (pt) | 2004-07-22 | 2014-11-03 | Genentech Inc | Composição de anticorpo her2 |
JP4904266B2 (ja) | 2004-07-26 | 2012-03-28 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 抗−tf−抗原抗体の治療的使用 |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
JP2008521828A (ja) | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス, インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
ES2710439T3 (es) | 2005-01-21 | 2019-04-25 | Genentech Inc | Dosificación fija de anticuerpos HER |
US20080226619A1 (en) * | 2005-01-28 | 2008-09-18 | Ramot At Tel Aviv University, Ltd. | Anti-Muc1 Alpha/Beta Antibodies |
DE102005009099A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel |
DE102005009084A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
US8858935B2 (en) | 2005-05-19 | 2014-10-14 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
CN101506238B (zh) | 2005-06-30 | 2013-11-06 | 森托科尔公司 | 具有提高治疗活性的方法和成分 |
GB0519398D0 (en) * | 2005-09-23 | 2005-11-02 | Antisoma Plc | Biological materials and uses thereof |
JP4919146B2 (ja) * | 2005-09-27 | 2012-04-18 | 独立行政法人産業技術総合研究所 | スイッチング素子 |
US20090181016A1 (en) | 2005-11-30 | 2009-07-16 | University Of Southern California | FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
WO2007093922A1 (en) | 2006-02-14 | 2007-08-23 | Koninklijke Philips Electronics N.V. | Bit detection for optical disc reading |
US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
PL1999154T3 (pl) | 2006-03-24 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe |
WO2007124992A1 (en) | 2006-04-28 | 2007-11-08 | Unilever N.V. | Method of manufacturing a cultured edible product comprising omega-3 polyunsaturated fatty acids |
PL2446904T3 (pl) | 2006-05-30 | 2015-10-30 | Genentech Inc | Przeciwciała anty-CD22, ich immunokoniugaty oraz ich zastosowania |
UA95958C2 (en) | 2006-05-30 | 2011-09-26 | Дженентек, Инк. | Antibody that binds to cd22, immunoconjugates and uses therefor |
ITMI20061473A1 (it) | 2006-07-26 | 2008-01-27 | Indena Spa | Derivati della camptotecina ad attivita antitumorale |
EP1900750A1 (en) | 2006-09-18 | 2008-03-19 | Glycotope Gmbh | Fully human high yield production system for improved antibodies |
KR20150126730A (ko) | 2006-09-10 | 2015-11-12 | 글리코토페 게엠베하 | 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도 |
EP1911766A1 (en) | 2006-10-13 | 2008-04-16 | Glycotope Gmbh | Use of human cells of myeloid leukaemia origin for expression of antibodies |
EP1920782A1 (en) | 2006-11-10 | 2008-05-14 | Glycotope Gmbh | Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof |
EP2109607A1 (en) | 2006-12-21 | 2009-10-21 | Schering Corporation | Pyrrolo[3, 2-a]pyridine derivatives for inhibiting ksp kinesin activity |
KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Erbb3에 대한 항체 및 이의 용도 |
US8450068B2 (en) | 2007-02-16 | 2013-05-28 | University Of Virginia Patent Foundation | IgE antibodies to chimeric or humanized IgG therapeutic monoclonal antibodies as a screening test for anaphylaxis |
CA2681159A1 (en) | 2007-03-13 | 2008-09-18 | Peros Systems Technologies, Inc. | Immunoactive compositions for improved oral delivery of vaccines and therapeutic agents |
CA2680111C (en) | 2007-03-22 | 2018-05-08 | Sloan-Kettering Institute For Cancer Research | Use of the anti-b7h3 (cd276) antibody, 8h9, for the treatment of neuroblastoma tumors |
ES2695047T3 (es) | 2007-04-03 | 2018-12-28 | Amgen Research (Munich) Gmbh | Dominio de unión específico entre especies |
HUE034763T2 (en) | 2008-04-30 | 2018-02-28 | Immunogen Inc | Crosslinkers and their use |
WO2009138220A1 (en) | 2008-05-13 | 2009-11-19 | Glycotope Gmbh | Fermentation process |
EP2277044B1 (en) | 2008-05-13 | 2015-06-17 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
RU2010153578A (ru) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойными вариабельными доменами и их применение |
EP2351777B1 (en) | 2008-10-28 | 2015-10-28 | Shionogi&Co., Ltd. | Anti-muc1 antibody |
BRPI0921586A2 (pt) | 2008-11-18 | 2019-09-24 | Merrimack Pharmaceuticals Inc | articuladores de albumina de soro humana e conjugados destes |
CN102448494B (zh) | 2009-02-13 | 2016-02-03 | 免疫医疗公司 | 具有胞内可裂解的键的免疫共轭物 |
US9079957B2 (en) | 2009-04-16 | 2015-07-14 | The University Of Tokyo | Diagnosis and treatment of cancer using anti-TMPRSS11E antibody |
BR112012001395A2 (pt) | 2009-07-22 | 2019-09-24 | Enzon Pharmaceuticals Inc | metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero |
EP2281844A1 (en) * | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
JP5829520B2 (ja) | 2009-08-20 | 2015-12-09 | 国立大学法人 千葉大学 | コルヒチン誘導体 |
JP2013505944A (ja) | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス, インコーポレイテッド | Dr5リガンド薬物結合体 |
MX357972B (es) | 2009-11-13 | 2018-08-01 | Amgen Inc | Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3. |
CA2782194C (en) | 2009-12-02 | 2018-01-16 | Immunomedics, Inc. | Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer |
JP5728718B2 (ja) * | 2009-12-28 | 2015-06-03 | オンコセラピー・サイエンス株式会社 | 抗cdh3抗体およびその使用 |
EP2347769A1 (en) | 2010-01-20 | 2011-07-27 | Glycotope GmbH | Cancer stem cell markers and uses thereof |
MX2012013001A (es) | 2010-05-13 | 2013-02-26 | Univ Indiana Res & Tech Corp | Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas. |
SG10201503904XA (en) | 2010-05-17 | 2015-06-29 | Livtech Inc | Anti-human trop-2 antibody having antitumor activity in vivo |
EA035193B1 (ru) | 2010-05-18 | 2020-05-14 | Серулин Фарма Инк. | Композиции и способы лечения аутоиммунных и других заболеваний |
JPWO2011155579A1 (ja) | 2010-06-10 | 2013-08-15 | 北海道公立大学法人 札幌医科大学 | 抗Trop−2抗体 |
BR112013000951A2 (pt) | 2010-07-12 | 2016-05-17 | Covx Technologies Ireland Ltd | conjungados de anticorpo multifuncionais |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
CA2815154A1 (en) | 2010-08-06 | 2012-02-09 | U3 Pharma Gmbh | Use of her3 binding agents in prostate treatment |
US9051370B2 (en) | 2010-08-10 | 2015-06-09 | Glycotope Gmbh | Humanized EGFR antibodies |
CA2805984C (en) | 2010-08-10 | 2021-05-25 | Glycotope Gmbh | Antibodies, functional fragments and derivatives having a sialylated fab region |
EP2638066A4 (en) | 2010-11-09 | 2015-06-03 | Medimmune Llc | ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION |
US20120121615A1 (en) | 2010-11-17 | 2012-05-17 | Flygare John A | Alaninyl maytansinol antibody conjugates |
US9175092B2 (en) | 2011-06-28 | 2015-11-03 | Oxford Biotherapeutics Ltd | Antibodies to bone marrow stromal antigen 1 |
AR088693A1 (es) | 2011-11-11 | 2014-06-25 | Rinat Neuroscience Corp | Anticuerpos especificos para trop-2 y sus usos |
US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
RU2014128467A (ru) | 2011-12-14 | 2016-02-10 | Сиэтл Дженетикс, Инк. | Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение |
AU2012356170B2 (en) | 2011-12-21 | 2016-06-16 | Novartis Ag | Compositions and methods for antibodies targeting Factor P |
US20130280282A1 (en) | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
US20150152187A1 (en) | 2012-06-14 | 2015-06-04 | Ambrx, Inc. | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides |
PT3342785T (pt) | 2012-10-11 | 2020-02-25 | Daiichi Sankyo Co Ltd | Ligantes para conjugados de anticorpo-fármaco |
EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
UA128182C2 (uk) | 2012-11-13 | 2024-05-01 | Біонтех Аґ | Агенти для лікування експресуючих клаудин ракових захворювань |
EP2927227A4 (en) | 2013-01-03 | 2015-12-30 | Celltrion Inc | ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH |
EP2945964A2 (en) | 2013-01-18 | 2015-11-25 | Glycotope GmbH | Fusion peptides for enhancing protein expression |
EP3027218A1 (en) * | 2013-08-02 | 2016-06-08 | Sanofi | Use of anti-muc1 maytansinoid immunoconjugate antibody for the treatment of solid tumors |
NZ720515A (en) | 2013-12-17 | 2022-12-23 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
KR102237803B1 (ko) | 2013-12-25 | 2021-04-09 | 다이이찌 산쿄 가부시키가이샤 | 항 trop2 항체-약물 컨쥬게이트 |
JP2015138634A (ja) | 2014-01-22 | 2015-07-30 | 株式会社オートネットワーク技術研究所 | 端子金具付き電線及びその製造方法 |
ES2794088T3 (es) * | 2014-01-29 | 2020-11-17 | Dana Farber Cancer Inst Inc | Anticuerpos contra el dominio extracelular de MUC1-C (MUC1-C/ECD) |
PT3101032T (pt) | 2014-01-31 | 2019-04-03 | Daiichi Sankyo Co Ltd | Onjugado de anticorpo anti-her2-fármaco |
PT3129063T (pt) | 2014-04-10 | 2021-04-01 | Daiichi Sankyo Europe Gmbh | Conjugado anticorpo anti-her3-fármaco |
GB201406767D0 (en) * | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
EP3150634B1 (en) | 2014-04-28 | 2020-04-22 | Medicinal Chemistry Pharmaceuticals Co., Ltd. | Anti-muc1 antibody or antigen-binding fragment thereof, and uses thereof |
KR102503476B1 (ko) | 2014-06-30 | 2023-02-24 | 알토 바이오사이언스 코포레이션 | Il-15-베이즈드 분자 및 이의 사용 방법 |
LU92659B1 (en) * | 2015-02-23 | 2016-08-24 | Glycotope Gmbh | Glycooptimized antibody drug conjugates |
JP6754532B2 (ja) | 2015-03-17 | 2020-09-16 | ティーアイエルティー・バイオセラピューティクス・オーワイTILT Biotherapeutics Oy | 二重特異性抗体をコードする腫瘍溶解性アデノウイルスおよびそれに関連する方法と使用 |
US10524738B2 (en) | 2015-05-04 | 2020-01-07 | Cercacor Laboratories, Inc. | Noninvasive sensor system with visual infographic display |
JP2020514304A (ja) | 2017-01-27 | 2020-05-21 | グリコトープ ゲーエムベーハー | 抗MUC1抗体およびErbB阻害剤を用いた抗がん処置 |
WO2018178122A1 (en) | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Pd-l1 and ta-muc1 antibodies |
WO2018178123A1 (en) | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | BISPECIFIC MUC-1 x PD-L1 ANTIBODIES |
CA3055433A1 (en) | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Humanized anti-cd40 antibodies |
KR20190134994A (ko) | 2017-03-29 | 2019-12-05 | 글리코토페 게엠베하 | Muc1 및 cd3에 결합하는 다중특이적 항체 작제물 |
US10561686B2 (en) | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
CN111819203A (zh) | 2018-03-01 | 2020-10-23 | 葛莱高托普有限公司 | 包含抗muc1抗体和il-15的融合蛋白构建体 |
SG11202010496WA (en) * | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
-
2019
- 2019-05-17 SG SG11202010496WA patent/SG11202010496WA/en unknown
- 2019-05-17 AU AU2019270457A patent/AU2019270457A1/en active Pending
- 2019-05-17 SG SG11202010493XA patent/SG11202010493XA/en unknown
- 2019-05-17 KR KR1020207036343A patent/KR20210010565A/ko unknown
- 2019-05-17 TW TW108117151A patent/TWI825098B/zh active
- 2019-05-17 CN CN202311750783.0A patent/CN117815404A/zh active Pending
- 2019-05-17 RS RS20230586A patent/RS64379B1/sr unknown
- 2019-05-17 JP JP2020564656A patent/JP7519910B2/ja active Active
- 2019-05-17 TW TW108117152A patent/TWI839357B/zh active
- 2019-05-17 MX MX2020011996A patent/MX2020011996A/es unknown
- 2019-05-17 TW TW112137234A patent/TW202402806A/zh unknown
- 2019-05-17 US US17/055,303 patent/US20210221910A1/en active Pending
- 2019-05-17 RS RS20240625A patent/RS65580B1/sr unknown
- 2019-05-17 FI FIEP19724824.8T patent/FI3794042T3/fi active
- 2019-05-17 WO PCT/EP2019/062756 patent/WO2019219889A1/en active Application Filing
- 2019-05-17 KR KR1020207036382A patent/KR20210013107A/ko unknown
- 2019-05-17 EP EP19724502.0A patent/EP3794041B1/en active Active
- 2019-05-17 WO PCT/EP2019/062758 patent/WO2019219891A1/en active Application Filing
- 2019-05-17 CA CA3100745A patent/CA3100745A1/en active Pending
- 2019-05-17 LT LTEPPCT/EP2019/062758T patent/LT3794042T/lt unknown
- 2019-05-17 HU HUE19724502A patent/HUE063066T2/hu unknown
- 2019-05-17 HR HRP20230787TT patent/HRP20230787T1/hr unknown
- 2019-05-17 CA CA3100608A patent/CA3100608A1/en active Pending
- 2019-05-17 PT PT197248248T patent/PT3794042T/pt unknown
- 2019-05-17 BR BR112020023373-0A patent/BR112020023373A2/pt unknown
- 2019-05-17 SI SI201930749T patent/SI3794042T1/sl unknown
- 2019-05-17 DK DK19724824.8T patent/DK3794042T5/da active
- 2019-05-17 EP EP23180419.6A patent/EP4257611A3/en active Pending
- 2019-05-17 CN CN201980033037.5A patent/CN112449641A/zh active Pending
- 2019-05-17 EP EP19724824.8A patent/EP3794042B1/en active Active
- 2019-05-17 JP JP2020564569A patent/JP7257422B2/ja active Active
- 2019-05-17 BR BR112020023346-3A patent/BR112020023346A2/pt unknown
- 2019-05-17 MX MX2020011997A patent/MX2020011997A/es unknown
- 2019-05-17 US US17/055,323 patent/US20210187118A1/en active Pending
- 2019-05-17 EP EP23174276.8A patent/EP4249002A3/en active Pending
- 2019-05-17 ES ES19724502T patent/ES2951674T3/es active Active
- 2019-05-17 PL PL19724502.0T patent/PL3794041T3/pl unknown
- 2019-05-17 CN CN201980033159.4A patent/CN112351999A/zh active Pending
- 2019-05-17 PL PL19724824.8T patent/PL3794042T3/pl unknown
- 2019-05-17 AU AU2019270459A patent/AU2019270459A1/en active Pending
-
2020
- 2020-10-27 ZA ZA2020/06684A patent/ZA202006684B/en unknown
- 2020-10-30 CO CONC2020/0013664A patent/CO2020013664A2/es unknown
- 2020-11-18 PH PH12020551969A patent/PH12020551969A1/en unknown
- 2020-11-18 PH PH12020551970A patent/PH12020551970A1/en unknown
- 2020-11-20 CO CONC2020/0014435A patent/CO2020014435A2/es unknown
-
2022
- 2022-08-01 US US17/878,611 patent/US11872289B2/en active Active
- 2022-12-13 JP JP2022198556A patent/JP7502402B2/ja active Active
-
2023
- 2023-07-10 US US18/349,438 patent/US20230372520A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202001219B (en) | Bcma monoclonal antibody-drug conjugate | |
RS65580B1 (sr) | Anti-muc1-eksatekan antitelo-lek konjugat | |
IL284280A (en) | Conjugate of antibody and oligonucleotide | |
IL272965A (en) | Improved methods of producing antibody-drug conjugates | |
EP3473270A4 (en) | ANTIBODY DRUG CONJUGATE | |
IL278990A (en) | Captures of camptothecin | |
IL273471B1 (en) | Conjugation of an antibody with a pyrrolobenzodiazepine derivative | |
IL268102A (en) | Anti-GPR 20 antibody and anti-GPR 20 antibody-drug conjugate | |
SG11202007919RA (en) | Antibody-drug conjugate having acidic self-stabilization junction | |
EP3501548A4 (en) | ANTIBODY-ACTIVE SUBSTANCE CONJUGATE TISSUE FABRIC FACTOR | |
HUE059828T2 (hu) | Pirrolobenzodiazepin konjugátumok | |
SG11202104993SA (en) | Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate | |
HK1257352A1 (zh) | 靶向gcc的抗體-藥物綴合物 | |
IL269321A (en) | drug-polymer couple | |
EP3620471A4 (en) | ANTIBODY-ANTI-FIBRIN DRUG CONJUGATE INSOLUBLE, POSSIBLE TO BE CLIVID BY PLASMINE | |
GB201820864D0 (en) | Antibody-drug conjugates | |
GB201820626D0 (en) | Conjugates | |
GB201917804D0 (en) | Conjugate | |
GB201913287D0 (en) | Anti-folate antibody-drug conjugate | |
IL288681A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201817110D0 (en) | Pyrrolobenzodiazepine conjugates | |
GB201817088D0 (en) | Pyrrolobenzodiazepine conjugates | |
GB201811332D0 (en) | Pyrroloobenzodiazepine-antibody conjugates | |
GB201811335D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201906997D0 (en) | Conjugates |